More from Author Ben Oakley here: https://globelivemedia.com/author/ben-oakley/

Globe Live Media, Monday, January 26, 2021
Spanish group Pharma Mar announced on Tuesday the confirmation of plitidepsin’s antiviral potential as a treatment against COVID-19, according to a company article published in the scientific journal Science.

The research shows that the plitidepsin compound works by blocking the protein eEF1A, present in human cells, and that it is used by SARS-CoV-2 to reproduce and infect other cells. This mechanism culminates in antiviral efficacy “in vivo”, said Pharma Mar.

“We believe that our data and the initial positive results from PharmaMar’s clinical trial suggest that plitidepsin should be seriously considered to expand clinical trials for the treatment of COVID-19,” the company said in a press release sent to the regulator.

 

The group added that the safety profile of plitidepsin was well established in humans.

Pharma Mar said it is currently negotiating with different regulatory bodies to start the planned phase III trials.

Categorized in:

News